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a b s t r a c t
Long-acting muscarinic receptor antagonists (LAMAs) and long-acting β2-adrenoceptor agonists (LABAs)
cause airway smooth muscle (ASM) relaxation via different signal transduction pathways, but there are
limited data concerning the interaction between these two drug classes on human bronchi. The aim of
this study was to investigate the potential synergistic interaction between aclidinium bromide and
formoterol fumarate on the relaxation of human ASM. We evaluated the inﬂuence of aclidinium bromide
and formoterol fumarate on the contractile response induced by acetylcholine or electrical ﬁeld
stimulation (EFS) on human isolated airways (segmental bronchi and bronchioles). We analyzed the
potential synergistic interaction between the compounds when administered in combination by using
Bliss independence (BI) theory. Both aclidinium bromide and formoterol fumarate completely relaxed
segmental bronchi pre-contracted with acetylcholine (Emax: 97.572.6% and 96.471.1%; pEC50 8.570.1
and 8.870.1; respectively). Formoterol fumarate, but not aclidinium bromide, abolished the contraction
induced by acetylcholine in bronchioles (Emax: 68.174.5% and 99.075.6%; pEC50 7.970.3 and 8.470.3;
respectively). The BI analysis indicated synergistic interaction at low concentrations in segmental
bronchi (þ18.472.7%; Po0.05 versus expected effect) and from low to high concentrations in
bronchioles (þ19.770.9%; Po0.05 versus expected effect). Low concentrations of both drugs produced
a synergistic relaxant interaction on isolated bronchi stimulated with EFS that was sustained for 6 h
post-treatment (þ55.179.4%; Po0.05 versus expected effect). These results suggest that combining
aclidinium bromide plus formoterol fumarate provides synergistic beneﬁt on ASM relaxation of both
medium and small human airways, which may have major implications for the use of this combination
in the clinic.
& 2014 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/3.0/).
1. Introduction
Bronchodilators are crucial for the management of symptoms of
chronic obstructive pulmonary disease (COPD) and asthma (GINA,
2012; GOLD, 2014). There are currently two classes of long-acting
bronchodilators with different pharmacological mechanisms: musca-
rinic receptor antagonists agents and β2-adrenoceptor agonists. Long-
acting muscarinic receptor antagonist (LAMAs) and long-acting β2-
adrenoceptor agonists (LABAs) are used for regular treatment of COPD,
whereas short-acting muscarinic receptor antagonists agents and
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short-acting β2-adrenoceptor agonists are used as rescue medications
for acute treatment of airways obstruction.
Combining a LAMA with a LABA might be a valuable therapeu-
tic approach for maintenance treatment of patients with stable-
moderate COPD whose symptoms are not adequately controlled
with monotherapy using the LAMA tiotropium bromide (Rodrigo
et al., 2012). Furthermore, it has been suggested that ﬁxed-dose
combination therapy with two classes of bronchodilator in the
same inhaler would simplify treatment regimens and improve
patient adherance (Cazzola and Matera, 2008).
A twice-daily ﬁxed-dose combination of the LAMA aclidinium
bromide and the LABA formoterol fumarate is currently under clinical
development for the treatment of COPD. The Phase III ACLIFORM
COPD study showed that aclidinium bromide/formoterol fumarate
400/6 μg and 400/12 μg signiﬁcantly improved 1-h post-dose forced
expiratory volume in 1 s (FEV1) versus aclidinium bromide mono-
therapy and trough FEV1 versus formoterol fumarate monotherapy at
Week 24 (Singh et al., 2014). Both parameters were signiﬁcantly
improved versus placebo and the ﬁndings of a second Phase III study
– AUGMENT COPD – were similar (D'Urzo et al., 2014).
Although these studies suggest that combining aclidinium
bromide with formoterol fumarate may be clinically useful, the full
extent of the interaction between these compounds is not yet well
understood. As LABAs and LAMAs both cause airways smooth
muscle (ASM) relaxation via different signal transduction pathways,
combining a LABA plus a LAMAmight prove beneﬁcial for a number
of reasons (Cazzola and Molimard, 2010). For example, LABAs
decrease the release of acetylcholine through modulation of choli-
nergic neurotransmission by acting on prejunctional β2-adrenor-
eceptors (β2-ARs) leading to the activation of calcium-activated
potassium channels that hyperpolarize the cell membrane, which
ampliﬁes the ASM relaxation induced by the LAMA. Furthermore,
LAMAs antagonize the bronchoconstrictor effects of acetylcholine,
whose release can be modiﬁed by the LABA, which may amplify the
bronchodilation induced by the LABA through the direct stimulation
of ASM β2-ARs (Cazzola and Molimard, 2010; Cazzola et al., 2013). In
addition, crosstalk between Gq-coupled M3 receptors and Gs-
coupled β2-ARs may inﬂuence the β-agonist-induced relaxation,
possibly by activation of protein kinase C (PKC) and subsequent
phosphorylation of β2-AR and/or Gs protein (Cazzola et al., 2013).
Although there is clear scientiﬁc rationale for combining
LAMAs and a LABAs in the treatment of COPD, to date there are
limited pharmacologic data investigating the interaction between
these drugs at the level of human bronchi. Therefore, the aim of
this study was to investigate the pharmacological interaction
between aclidinium bromide and formoterol fumarate on the
relaxation of human segmental bronchi. In addition, small airways
were evaluated in order to better understand the interaction
between these drugs on ASM found at different anatomical levels
of human respiratory tract.
2. Material and methods
2.1. Ethical approval and informed consent
Ethical approval and informed consent were obtained from the
Istituto Regina Elena – Istituto San Gallicano (Rome, Italy) and they
were consistent with the 2009 National Committee of Bioethics,
National Committee of Bio-safety, Biotechnology and Sciences (Italy)
recommendations on the collection of biological samples for research
purposes, the 2010 Italian ethical and legal recommendations con-
cerning the biobank, and the research biorepository (Istituto Nazionale
dei Tumore – Independent Ethics Committee, 2010), and the Comitato
Nazionale per la Biosicurezza, le Biotecnologie e le Scienze per la Vita
(Raccolta di campioni biologici a ﬁni di reicerca, consenso informato,
2009; available at: http://www.governo.it/bioetica/gruppo_misto/Con
senso_Informato_allegato_Petrini_2009.pdf).
2.2. Preparation of tissues
Regions of macroscopically normal lungs were taken from
uninvolved areas resected from 23 patients (14 male, 9 female;
aged 63.172.2 years) undergoing lobectomy for lung cancer, but
without a history of chronic airway disease.
Tissue samples were immediately placed into oxygenated
Krebs-Henseleit (KH) buffer solution (NaCl 119.0 mM, KCl
5.4 mM, CaCl2 2.5 mM, KH2PO4 1.2 mM, MgSO4 1.2 mM, NaHCO3
25.0 mM, glucose 11.7 mM; pH 7.4) containing the cyclooxygenase
inhibitor indomethacin (5.0 μM), and transported at 4 1C from the
Regina Elena National Cancer Institute (Rome, Italy) to the Labora-
tory of Respiratory Pharmacology in the Medical School of the
University of Rome “Tor Vergata” (Rome, Italy). None of the
patients had been chronically treated with theophylline, β2-
agonists, or glucocorticosteroids. Serum immunoglobulin E levels
determined on the day of surgery were in the normal range.
Preoperative lung function parameters were generally normal and
there were no signs of respiratory infections.
In the laboratory, airways were dissected from connective and
alveolar tissues and refrigerated overnight in KH buffer solution. The
next morning, bronchi were cut into rings (medium airways,
segmental bronchi; thickness: 1–2 mm; diameter: 4–6 mm) and
transferred into a 10 ml High Tech 8 Channels Manual Compact
Organ Bath system (Panlab Harvard Apparatus, Spain) containing KH
buffer solution (37 1C) and continuously aerated with O2/CO2 (95:5%).
Precision-cut lung slices (PCLSs) were sectioned (small airways,
bronchioles; thickness: o500 mm; diameter: 0.9370.08 mm)
using a Vibroslice Microtome equipped with ceramic blades
(Campden Instruments, UK). Slices were processed without the
complications related to the use of confounding agarose gel to
inﬂate the lung or complex parenchymal sections that have
numerous contracting elements (Calzetta et al., 2014b; van
Lunteren and Moyer, 2001; Wohlsen et al., 2001). PCLSs were
mounted into a Visual Imaging and Patching Chamber connected
to a Proportional Integral Derivative Temperature Controller with
dual thermistor feedback CI7800 (Campden Instruments, UK),
containing KH buffer solution (37 1C) and continuously aerated
with O2/CO2 (95:5%).
2.3. Preparation of drugs
Test compounds were maintained under dry conditions and
prepared daily. Stock solutions used in this study were: acetylcholine
(Sigma-Aldrich, Italy), papaverine (Sigma-Aldrich, Italy), indometha-
cin (Sigma-Aldrich, Italy), formoterol fumarate (a kind gift from
Almirall, Spain), and aclidinium bromide (a kind gift from Almirall,
Spain). All products were dissolved in distilled water, except aclidi-
nium bromide, which was dissolved in 1N HCl 1% (v/v). Indometha-
cin was dissolved in pure ethanol and diluted in KH buffer solution
prior to use. The maximal concentration of ethanol used to prepare
drug solutions (0.02%) did not inﬂuence isolated tissue responses as
reported elsewhere (Freas et al., 1989; Hatake and Wakabayashi,
2000). Appropriate dilutions were obtained in freshly prepared
medium. Stock solutions were stored at 80 1C until use.
2.4. Measurement of bronchial smooth muscle contraction
Each bronchial ring was connected to an isometric force
transducer (Fort25; WPI, UK) and was allowed to equilibrate for
90 min before being ﬂushed with fresh KH buffer solution every
10 min. The signal was ampliﬁed by a Powerlab 8/36 and Octal
Bridge Amp system (AD instruments, UK) and recorded and
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analyzed with LabChart 7 interface software (AD instruments, UK).
Passive tension was determined by gentle stretching of the tissue
(0.5–1.0 g) during equilibration. The transducer measured the
isometric change in tension and tissue responsiveness was
assessed using acetylcholine (100 mM) or electrical-ﬁeld stimula-
tion (EFS) at 10 Hz. When the contractile response reached a
plateau, the bronchial rings were washed three times and allowed
to equilibrate further.
Videomicrometry of small airway preparations was assessed
using a stereo microscope (SZR-10 Zenith, Italy) and a digital
Optikam-B5 managed by OptikaView 7 Software (Optika Micro-
scopes, Italy). The small airways were continuously ﬂushed with
KH buffer solution for 90 min to allow them to equilibrate and to
ensure that the luminal area was stable. The luminal area was
measured using image processing and analysis software Image J
(National Institutes of Health, Bethesda, USA).
2.5. Study design
2.5.1. Study 1: evaluation of the interaction between aclidinium
bromide and formoterol fumarate on the relaxation of human
segmental bronchi and small airways pre-contracted with
acetylcholine
Following equilibration of the tissues, bronchial rings/PCLSs
were submaximally contracted with acetylcholine (70% of max-
imal contraction [EC70]). Experiments were carried out in an
isolated organ bath system or in a videomicrometry system to
evaluate the relaxation associated with ASM strength and the
related increase in intraluminal bronchial area.
After approximately 15 min at plateau, semi-logarithmic con-
centration-response curves (CRCs) to aclidinium bromide and/or
formoterol fumarate, alone or in combination, were constructed at
a range of isoeffective concentrations from 0.1 nM to 10 mM for
each compound. Each CRC was obtained by the cumulative
addition of aclidinium bromide and/or formoterol fumarate at
5–15 min intervals to reach a stable level of relaxation before the
next concentration was administered.
A cumulative concentration of vehicle was used as a time
control. At the end of the experiments, papaverine (100 μM) was
added to the bronchial rings and PCLSs to determine the maximal
relaxant response (Emax) achievable for each isolated bronchus.
2.5.2. Study 2: an investigation of the time course of the interaction
between aclidinium bromide and formoterol fumarate on the
relaxation of human isolated segmental bronchi contracted by EFS
Contractile responses were induced by EFS, delivered by
using bipolar platinum electrodes (2Biological Instruments, Italy),
10 mm apart, connected to a 3165 Multiplexing Pulse Booster
stimulator (Ugo Basile, Italy).
Trains of 10 Hz EFS were delivered (biphasic pulse with a
constant current of 10 V, 0.5 ms, 10 s) with one pulse every
5–10 min in order to simulate vagus nerve ﬁring as previously
described (Cazzola et al. 2011).
The concentration of aclidinum bromide and formoterol fuma-
rate required to induce 20% relaxation (EC20) was determined in
bronchial rings contracted by EFS. The EC20 of each compound was
then used to assess the time cover of the relaxant effect in isolated
bronchi contracted by EFS at 10 Hz for up to 12 h.
In further experiments, after initiating EFS, bronchi were
treated with aclidinium bromide and formoterol fumarate for
60 min, either alone or in combination, with the EC20 for each
drug. Tissue samples were then washed three times before being
ﬂushed with KH buffer solution (30 mL/h) for 12 h. Papaverine
(100 μM) was then added to the bronchial rings to determine the
Emax achievable for each isolated bronchus.
2.6. Data analysis
2.6.1. Study 1
The extent of relaxation of isolated bronchial rings and PCLSs
was expressed as a percentage of the Emax (contractile tone
reduction and luminal area enhancement, respectively) induced
by papaverine (100 mM) on the plateau response induced by
acetylcholine EC70.
Appropriate curve-ﬁtting to a sigmoidal model was used to
calculate the effect (E), the Emax, the dose inducing 50% Emax (EC50),
and the EC70. The equation used was log (agonist; antagonist) versus
response, Variable slope, expressed as Y¼Bottomþ(TopBottom)/
{1þ10[(log EC50X)nHillSlope]}. For statistical analysis of the
potency, the pEC50 value was used where pEC50¼ log EC50 as
described elsewhere (Motulsky and Christopoulos, 2004).
2.6.2. Study 2
The contractile response to EFS was expressed as a percentage
of the effect induced by control EFS preceding treatment with
aclidinium bromide or formoterol fumarate. Polynomial curves
were constructed by ﬁtting models of biological data using non-
linear regression as described elsewhere (Motulsky and
Christopoulos, 2004). The Emax (% reduction of the EFS contractile
tension) and the onset of action (time to evoke half maximal
relaxation) were identiﬁed. One in every seven bronchial rings was
used as a time control.
2.6.3. Interaction analysis
The interaction of aclidinium bromide and formoterol fumarate
on the relaxation of human isolated bronchi was evaluated using
the Bliss independence (BI) theory, that provides outcomes for the
expected additive response for the combination. Different speci-
mens from every donor received LAMA, LABA and the combination
separately and all treatments have been performed by randomiza-
tion schedule. The main assumption of BI theory is that two or
more agents act independently of each other with the mode and,
possibly, the site of action of the compounds differing from
each other.
BI theory for two agents is expressed by the equation:
Eðx; yÞ ¼ ExþEyðExnEyÞ
where E is the fractional effect, and x and y are the doses of two
compounds in a combination experiment. If the combination
effect is higher than the expected value, the interaction is
synergistic; if it is lower than the expected value, the interaction
is antagonistic; otherwise, the effect is considered additive with no
interaction as described elsewhere (Boik et al., 2008; Boucher and
Tam, 2006; Goldoni and Johansson, 2007; Greco et al., 1995; Lee,
2010; Meletiadis et al., 2003).
In Studies 1 and 2, ‘x’ and ‘y’ in the BI equation are aclidinium
bromide and formoterol fumarate, respectively. The BI equation
was used to establish the expected relaxant effect induced by the
interaction of aclidinium bromide plus formoterol fumarate at
isoeffective concentrations.
2.6.4. Statistical analysis
Values have been presented as mean7standard error of the
mean of 3 bronchi obtained from different donors. Statistical
signiﬁcance was assessed by a t test or one-way analysis of
variance (ANOVA) with Bonferroni's and Dunnet's multiple com-
parison tests when necessary. Statistical signiﬁcance was deﬁned
as Po0.05. Data analyses were performed using Prism 5 software
(GraphPad Software Inc, CA, USA).
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3. Results
3.1. Study 1
3.1.1. Contractile tone of isolated segmental bronchi
Both aclidinium bromide and formoterol fumarate induced
potent concentration-dependent relaxation of human isolated
bronchi submaximally pre-contracted with acetylcholine (aclidi-
nium bromide pEC50: 8.5170.13; formoterol fumarate pEC50:
8.7670.05), and the potency of these drugs was not signiﬁcantly
different (P40.05). Aclidinium bromide and formoterol fumarate
completely abolished the contractile tone induced by acetylcholine
EC70 (acetylcholine EC70: 9.2172.50 μM; aclidinium bromide
Emax: 97.4972.57%; formoterol fumarate Emax: 96.4471.13%)
(Fig. 1A). Vehicle had no effect on bronchial tone.
There was a signiﬁcant difference (Po0.05) between the slope
of the CRCs obtained with aclidinium bromide (0.7470.13) and
formoterol fumarate (1.1870.12). Therefore, a study of the corre-
lation between the drug concentrations and E, expressed as
percentage of Emax, was carried out to identify the isoeffective
relaxant concentrations for each drug (Fig. 1B).
Aclidinium bromide plus formoterol fumarate induced a sig-
niﬁcant synergistic relaxant response in human isolated bronchi
submaximally pre-contracted with acetylcholine, compared with
the expected response predicted by BI theory (Po0.05) (Fig. 1C).
The synergistic interaction was observed at low concentrations
(aclidinium bromide 1.15–2.15 nM; formoterol fumarate 0.84–
1.20 nM) and induced an increased relaxant response of
þ18.3772.72%, compared with the expected additive response
predicted by BI theory (Fig. 1D).
These results were conﬁrmed by the analysis of interaction for
low (EC20 and EC30) and high concentrations (EC80), where low
concentrations of aclidinium bromide and formoterol fumarate,
which alone would have achieved 30% relaxation of bronchi, together
induced a signiﬁcant relaxation of 69.3172.59% (Po0.05) (Fig. 3A),
whereas no synergistic interaction was detected at high concentra-
tions (expected response versus observed response: P40.05, data
not shown).
3.1.2. Videomicrometry of bronchioles
Both aclidinium bromide and formoterol fumarate induced a
potent concentration-dependent relaxation of human PCLSs sub-
maximally pre-contracted with acetylcholine (acetylcholine EC70:
3.2070.72 μM; aclidinium bromide pEC50: 7.9370.26; formo-
terol fumarate pEC50: 8.3770.28) and the potency of these drugs
was not signiﬁcantly different (P40.05). Formoterol fumarate, but
not aclidinium bromide, completely abolished the bronchial con-
traction induced by acetylcholine EC70 (aclidinium bromide Emax:
68.0774.47%; formoterol fumarate Emax: 98.9975.61%; Po0.05)
(Fig. 1C). Vehicle did not signiﬁcantly modify the bronchial tone
(P40.05).
There was a difference between the slope of the CRCs obtained
with aclidinium bromide (0.7870.37) and formoterol fumarate
(0.4170.1). Consequently, a study of the correlation between the
drug doses and E, expressed as percentage of Emax, was carried out
to identify the isoeffective relaxant concentrations for both acli-
dinium bromide and formoterol fumarate (Fig. 1D).
Aclidinium bromide plus formoterol fumarate induced a signiﬁcant
(Po0.05) synergistic relaxant response in human PCLSs submaximally
pre-contracted with acetylcholine compared with the expected
response predicted by BI theory (Fig. 2C). In particular, the interaction
between aclidinium bromide plus formoterol fumarate was synergistic
across the full concentration range used (aclidinium bromide: 3.2 nM–
1.0 μM, formoterol fumarate 1.8–63.0 nM) and an increased relaxant
response of þ19.6770.85% was induced compared with the expected
additive response predicted by BI theory (Fig. 2D).
The interaction analysis indicated that low concentrations of
aclidinium bromide plus formoterol fumarate induced a signiﬁcant
(Po0.05) luminal area enhancement of 69.8972.28%, whereas
the individual compounds would have elicited a luminal area
enhancement of 30% (Fig. 3B).
3.2. Study 2
The EC20 of aclidinium bromide and formoterol fumarate in
bronchial rings contracted by EFS was 1.6070.32 nM and
1.6070.27 nM, respectively.
As expected, neither aclidinium bromide nor formoterol fuma-
rate administered alone was able to reduce the contractile
response to EFS by 50% at EC20. However, the isoeffective mixture
of aclidinium bromide plus formoterol fumarate at EC20 produced
a maximal relaxation of 69.7476.35% and the relaxant effect
increased to 82.3672.54% at the 198th minute of the experiment.
The onset of action of the relaxant effect for aclidinium bromide
plus formoterol fumarate was 15.573.5 min that remained stable
up to the twelfth hour of the study (74.3477.88%, Fig. 4A).
From 0–6 h, the average observed relaxant effect was
68.4972.21%, which was signiﬁcantly higher than that predicted
by BI theory (38.5571.94%; Po0.001).
Low concentrations of aclidinium bromide plus formoterol
fumarate produced a signiﬁcant (Po0.001) synergistic relaxant
interaction on EFS-induced contraction of human isolated bronchi
that was sustained for 6 h post-treatment (Fig. 4B). The maximal
increased relaxant response was þ55.1279.37%, which was
greater than the expected additive response predicted by BI
theory, and achieved at the 84th minute of the study.
4. Discussion
The combination of a LABA plus a LAMA has been suggested as
a rational approach to treating patients with moderate to severe
COPD (Cazzola and Molimard, 2010; Tashkin and Ferguson, 2013).
Unfortunately, to date relatively few studies have examined the
interaction between LABAs and LAMAs, although some have
documented beneﬁts on lung function and other outcomes com-
pared with the individual drug classes used alone (Tashkin and
Ferguson, 2013). There remains a paucity of preclinical data
investigating the interaction between LAMAs and LABAs and it is
unclear whether additive or synergistic interactions occur when
these drug classes are combined.
In this study we have demonstrated that aclidinium bromide
and formoterol fumarate administered alone both induced potent,
signiﬁcant, and long lasting relaxation of human isolated segmental
bronchi. However, when administered together and at low con-
centrations, these drugs showed synergistic inhibition of ASM tone
induced by either EFS or contraction with a cholinergic agonist. This
extends and supports observations previously reported in animals,
where a favorable interaction between a LABA and a LAMA has been
documented in the control of airway changes induced by different
challenges in guinea-pigs (Rossoni et al., 2007).
Both aclidinium bromide and formoterol fumarate caused
time-dependent inhibition of the contractile response elicited by
EFS, conﬁrming the long duration of action of these compounds in
human isolated bronchi. Intriguingly, the combination produced a
synergistic interaction that induced a considerably faster onset of
action on the reduction of the EFS-induced contractile tone, and
this relaxant effect was maintained for up to 6 h after administra-
tion of the drugs.
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Aclidinium bromide and formoterol fumarate also demonstrated
a potent relaxant effect in small human airways, and formoterol
fumarate – but not aclidinium bromide – completely relaxed
bronchioles. In addition, the combination was particularly effective
at inhibiting the contractile response of human bronchioles, with a
wider extent of synergistic interaction from low to high concentra-
tions compared with observations in larger isolated bronchi.
These data provide evidence that the concomitant administra-
tion of aclidinium bromide and formoterol fumarate at low
concentrations leads to improved relaxation of both medium and
small airways when compared with either drug administered
alone. These ﬁndings are consistent with those seen in a Phase
III clinical study evaluating the bronchodilator effect of a ﬁxed-
dose combination of aclidinium bromide/formoterol fumarate in a
multi-dose dry powder inhaler (Singh et al., 2014). These data are
also consistent with observations with other combinations of β2-
adrenoceptor agonists and antimuscarinic compounds, providing a
good basis for explaining the improved clinical data reported with
ﬁxed-dose combinations of a LABA and a LAMA (Tashkin and
Ferguson, 2013).
The BI theory used in our study to analyze the drug interaction
is generally applied to investigate combined effects of drugs and it
has been extensively validated experimentally using in vitro
human airway smooth muscle preparations (Calzetta et al., 2013;
Rogliani et al., 2013). The main assumption of the BI theory is that
two or more agents act independently from one another in terms
of site of action of the drugs in the mixture (Goldoni and
Johansson, 2007; Greco et al., 1995). The validity of the BI model
Fig. 1. Inﬂuence of aclidinium bromide and formoterol fumarate on the contractile tone of human segmental bronchi (A) submaximally pre-contracted with acetylcholine
(EC70) and concentrations inducing isoeffective relaxation (B). Expected and observed relaxant response induced by aclidinium bromide plus formoterol fumarate in human
segmental bronchi (C) submaximally pre-contracted with acetylcholine (EC70) and delta effect between observed and expected relaxant response (D). nPo0.05 versus
expected relaxant response as predicted by the Bliss independence theory. EC, effective concentration; EC70, effective concentration for 70% of maximal effect; Emax, maximal
effect; subMAX, submaximal.
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might be questioned for drugs with very steep CRCs because, in
such cases, this mathematical model tends to overestimate the
synergy. As the potential overestimation occurs for Hill Slope 42,
we can consider the BI criterion adequate for evaluating the
synergistic interaction in our study as the slope of the CRCs for
aclidinium bromide and formoterol fumarate were always o1.2
(Goldoni and Johansson, 2007). Therefore, the BI method applied
to our experiments permitted an accurate statistical analysis with
high biological plausibility that would not be possible by other
pharmacological interaction analysis methods such as the Beren-
baum approach and the dose-equivalence approach (Berenbaum,
1989; Goldoni and Johansson, 2007; Greco et al., 1995; Lee, 2010;
Tallarida, 2001). The BI approach also has the advantage of
allowing analysis of single combination points, as carried out in
our study for investigating low concentration interactions at EC20
and EC30 (Goldoni and Johansson, 2007).
Our ﬁndings support the scientiﬁc rationale for combining
aclidinium bromide and formoterol fumarate at low concentra-
tions in order to optimize airway smooth muscle relaxation.
Obviously, it is now of interest to identify the most favorable
dosage of this drug combination to achieve optimal bronchodila-
tion in patients with COPD via this synergistic interaction. This
would also potentially allow improved bronchodilation while
reducing the possibility of adverse events.
The results from the current study demonstrate that the LAMA
alone, unlike the LABA, was unable to completely relax the tone
Fig. 2. Inﬂuence of aclidinium bromide and formoterol fumarate on the luminal area of human bronchioles (A) submaximally pre-contracted with acetylcholine (EC70) and
concentrations inducing isoeffective relaxation (B). Expected and observed relaxant response induced by aclidinium bromide plus formoterol fumarate of human bronchioles
(C) submaximally pre-contracted with acetylcholine (EC70) and delta effect between observed and expected relaxant response (D). nPo0.05 versus expected relaxant
response as predicted by the Bliss independence theory. EC, effective concentration; EC70, effective concentration for 70% of maximal effect; Emax, maximal effect; subMAX,
submaximal.
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induced by acetylcholine in the small airways. This ﬁnding is in
agreement with the fact that, while the density of β2-ARs in ASM
does not change at different airway levels, the density of muscari-
nic receptors is greater in larger airways compared with bronch-
ioles (Barnes, 2004). Intriguingly however, the combination of
aclidinium bromide plus formoterol fumarate at low concentra-
tions completely prevented the bronchoconstriction induced by
acetylcholine, even at the level of small airways. Therefore, the
greater effectiveness of a LAMA plus a LABA combination on small
airways, compared with the partial effect of LAMA alone, might be
of clinical relevance for improving air–trapping related to the
obstruction of bronchioles – an important but neglected treatment
target in COPD (Sturton et al., 2008).
Since the bronchodilation achieved by aclidinium bromide
might be inﬂuenced by the extent of M3 muscarinic receptor
activation, we standardized the bronchial contractility at EC70, as
reported in previous studies (Calzetta et al., 2013, 2014a; Cazzola
et al., 2014; Matera et al., 2009, 2011b; Rogliani et al., 2013). This
approach, that allow inducing submaximal airways contraction,
permitted also to adequately investigate the effect of the LABA
formoterol fumarate on the bronchial tone produced by choliner-
gic activation. Although we cannot exclude a functional synergistic
interaction due to the effect of different drugs on different path-
ways, such as inhibiting muscarinic tone by LAMA and stimulating
relaxant response cAMP-mediated by LABA, we cannot rule out
more sophisticated interactions concerning the intracellular cross-
talking between muscarinic M2, M3 and β2-ARs. In fact, post-
synaptic Gi-coupled M2 muscarinic receptors inhibit adenylyl
cyclase reducing the β2-ARs mediated cAMP production and alter
the hyperpolarazion of Ca2þ dependent Kþ channels via Gβγ
subunits (Meurs et al., 2013). Furthermore, cross-talk between Gq-
coupled M3 receptors and Gs-coupled β2-AR may modify the
bronchial relaxation by inducing desensitization of β2-AR and
Gs-proteins via PKC induced phosphorylation (Meurs et al.,
2013). Overall, these intracellular crass-talking makes the mus-
carinic and the β-adrenoceptor pathways so linked to justify a
potential mechanistic interaction between LAMAs and LABAs.
However, although we have demonstrated the presence of syner-
gistic interaction between these compounds, further speciﬁc basic
research is needed to pharmacologically characterize the nature of
this synergism (Cazzola and Molimard, 2010).
The latest update of the Global initiative for chronic Obstructive
Lung Disease guidelines recommends the combination of two
long-acting bronchodilators with differing modes of action in
patients with COPD that is not adequately controlled with mono-
therapy (GOLD, 2014) and we believe the data obtained from the
present study give support to this recommendation. Our results
also suggest that the synergistic interaction observed when
combining a LABA plus a LAMA might, theoretically, also have
the potential to improve the bronchodilator response in a syner-
gistic manner, without the need to increase the dose of either
component (Cazzola and Tashkin, 2009). However, there are
very few studies in the literature investigating the potential
interaction between LABAs and LAMAs and this information
has mainly come from the investigation of the combination of
tiotropium plus olodaterol on ovalbumin-induced bronchocon-
striction in anesthetized guinea-pigs and on acetylcholine-
induced bronchoconstriction in anesthetized dogs (Bouyssou
et al., 2010, 2011).
To the best of our knowledge, this is the ﬁrst study that has
pharmacologically conﬁrmed under controlled experimental set-
tings the synergistic interaction between LABAs and LAMAs in
relaxing both medium and small isolated human airways.
Although the response of isolated human ASM may not always
be identical to that elicited in vivo, isolated airway preparations
provide a suitable, convenient, and reproducible biological model
for the evaluation of drug effects on ASM independent from the
potential systemic inﬂuences found in vivo (Endoh and Hori, 2006;
Iglarz et al., 2008). In particular, the conﬁguration of the smooth
muscle bundles is largely preserved in human isolated bronchi and
therefore the bronchial contraction is directly related to airway
narrowing (Calzetta et al., 2011, 2013; Cazzola et al., 2011, 2012;
Hewson et al., 2012; Hulsmann and de Jongste, 1993; Matera et al.,
2005, 2008, 2009, 2011a, 2011b; Rogliani et al., 2013).
In conclusion, although this study was conducted on airways
collected from patients without history of chronic airway diseases,
our results suggest that the hypothesis of combining a LABA and a
LABA in the treatment of patients with COPD might have a rational
by providing synergistic beneﬁt on ASM relaxation of both
Fig. 3. Analysis of interaction between isoeffective low (EC20 and EC30) concentra-
tions of aclidinium bromide plus formoterol fumarate in human segmental bronchi
(A) and human bronchioles (B) submaximally pre-contracted with acetylcholine
(EC70). nPo0.05 versus expected relaxant response as predicted by the Bliss
independence theory. EC20, effective concentration for 20% of maximal effect;
EC30, effective concentration for 30% of maximal effect; EC70, effective concentra-
tion for 70% of maximal effect; subMAX, submaximal.
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medium and small human airways, which, in turn, may have major
implications for the use of such combinations in the clinic.
Authorship contributions
Participated in research design: Cazzola, Calzetta, Page,
Rogliani, Gavaldà, Matera.
Conducted experiments: Calzetta, Facciolo.
Contributed new reagents or analytic tools: Gavaldà.
Performed data analysis: Calzetta.
Wrote or contributed to the writing of the manuscript: Cazzola,
Calzetta, Page, Rogliani, Matera.
Acknowledgments
This study was supported by Almirall S.A., Barcelona, Spain.
Medical writing assistance, funded by Almirall S.A., was provided
by Richard Knight, PhD and Suzanne McAllister, PhD, of Complete
Medical Communications.
References
Barnes, P.J., 2004. Distribution of receptor targets in the lung. Proc. Am. Thorac. Soc.
1, 345–351.
Berenbaum, M.C., 1989. What is synergy? Pharmacol. Rev. 41, 93–141.
Fig. 4. Duration of action (A) and delta effect between observed and expected relaxant response (B) for aclidinium bromide and formoterol fumarate in human isolated
bronchi stimulated with EFS at 10 Hz for mimicking the vagus nerve ﬁring during the 12-h study. nnnPo0.001 versus expected relaxant response as predicted by the Bliss
independence theory. E, effect; EC20, effective concentration for 20% of maximal effect; EFS, electrical ﬁeld stimulation.
M. Cazzola et al. / European Journal of Pharmacology 745 (2014) 135–143142
Boik, J.C., Newman, R.A., Boik, R.J., 2008. Quantifying synergism/antagonism using
nonlinear mixed-effects modeling: a simulation study. Stat. Med. 27,
1040–1061.
Boucher, A.N., Tam, V.H., 2006. Mathematical formulation of additivity for anti-
microbial agents. Diagn. Microbiol. Infect. Dis. 55, 319–325.
Bouyssou, T., Casarosa, P., Pieper, M., Schnapp, A., Gantner, F., 2011. Synergistic
bronchoprotective activity of the long-acting beta 2-agonist olodaterol with
tiotropium (long-acting M3 antagonist) and ciclesonide (inhaled steroid) on the
ovalbumin-induced bronchoconstriction in anaesthetized guinea pigs. Eur.
Respir. J. 38 (Suppl. 55), 613s.
Bouyssou, T., Schnapp, A., Casarosa, P., Pieper, M., 2010. Addition Of The New Once-
daily LABA BI 1744 to tiotropium results in superior bronchoprotection in pre-
clinical models. Am. J. Respir. Crit. Care Med. 181.
Calzetta, L., Page, C.P., Spina, D., Cazzola, M., Rogliani, P., Facciolo, F., Matera, M.G.,
2013. Effect of the mixed phosphodiesterase 3/4 inhibitor RPL554 on human
isolated bronchial smooth muscle tone. J. Pharmacol. Exp. Ther. 346, 414–423.
Calzetta, L., Passeri, D., Kanabar, V., Rogliani, P., Page, C., Cazzola, M., Matera, M.G.,
Orlandi, A., 2014a. Brain natriuretic peptide protects against hyperresponsive-
ness of human asthmatic airway smooth muscle via an epithelial cell-
dependent mechanism. Am. J. Respir. Cell Mol. Biol. 50, 493–501.
Calzetta, L., Rogliani, P., Cazzola, M., Matera, M.G., 2014b. Advances in asthma drug
discovery: evaluating the potential of nasal cell sampling and beyond. Expert
Opin.Drug Discov.
Calzetta, L., Spina, D., Cazzola, M., Page, C.P., Facciolo, F., Rendina, E.A., Matera, M.G.,
2011. Pharmacological characterization of adenosine receptors on isolated
human bronchi. Am. J. Respir. Cell Mol. Biol. 45, 1222–1231.
Cazzola, M., Calzetta, L., Page, C.P., Rinaldi, B., Capuano, A., Matera, M.G., 2011.
Protein prenylation contributes to the effects of LPS on EFS-induced responses
in human isolated bronchi. Am. J. Respir. Cell Mol. Biol. 45, 704–710.
Cazzola, M., Calzetta, L., Rogliani, P., Lauro, D., Novelli, L., Page, C.P., Kanabar, V.,
Matera, M.G., 2012. High glucose enhances responsiveness of human airways
smooth muscle via the Rho/ROCK pathway. Am. J. Respir. Cell Mol. Biol. 47,
509–516.
Cazzola, M., Calzetta, L., Segreti, A., Facciolo, F., Rogliani, P., Matera, M.G., 2014.
Translational study searching for synergy between glycopyrronium and inda-
caterol. COPD.
Cazzola, M., Matera, M.G., 2008. Novel long-acting bronchodilators for COPD and
asthma. Br. J. Pharmacol. 155, 291–299.
Cazzola, M., Molimard, M., 2010. The scientiﬁc rationale for combining long-acting
beta2-agonists and muscarinic antagonists in COPD. Pulm. Pharmacol. Ther. 23,
257–267.
Cazzola, M., Segreti, A., Matera, M.G., 2013. New developments in the combination
treatment of COPD: focus on umeclidinium/vilanterol. Drug Des. Dev. Ther. 7,
1201–1208.
Cazzola, M., Tashkin, D.P., 2009. Combination of formoterol and tiotropium in the
treatment of COPD: effects on lung function. COPD 6, 404–415.
D'Urzo, A., Rennard, S., Mergel, V., Garcia Gil, E., Leselbaum, A., Caracta, C., 2014. The
AUGMENT COPD trial: efﬁcacy and safety of a ﬁxed-dose combination of
aclidinium bromide and formoterol fumarate in COPD patients. Chest 145,
426A.
Endoh, M., Hori, M., 2006. Acute heart failure: inotropic agents and their clinical
uses. Expert Opin. Pharmacother. 7, 2179–2202.
Freas, W., Hart, J.L., Golightly, D., McClure, H., Muldoon, S.M., 1989. Contractile
properties of isolated vascular smooth muscle after photoradiation. Am. J.
Physiol. 256, H655–H664.
GINA, 2012. Global Strategy for Asthma Management and Prevention. Global
Initiative for Asthma (GINA) 〈http://www.ginasthma.org/〉.
GOLD, 2014. Global Strategy for the Diagnosis, Management and Prevention of
COPD. Global Initiative for Chronic Obstructive Lung Disease (GOLD) 〈http://
www.goldcopd.org/〉.
Goldoni, M., Johansson, C., 2007. A mathematical approach to study combined
effects of toxicants in vitro: evaluation of the Bliss independence criterion and
the Loewe additivity model. Toxicol. In Vitro 21, 759–769.
Greco, W.R., Bravo, G., Parsons, J.C., 1995. The search for synergy: a critical review
from a response surface perspective. Pharmacol. Rev. 47, 331–385.
Hatake, K., Wakabayashi, I., 2000. Ethanol suppresses L-arginine-induced relaxation
response of rat aorta stimulated with bacterial lipopolysaccharide. Nihon
Arukoru Yakubutsu Igakkai Zasshi 35, 61–68.
Hewson, C.A., Patel, S., Calzetta, L., Campwala, H., Havard, S., Luscombe, E., Clarke,
P.A., Peachell, P.T., Matera, M.G., Cazzola, M., Page, C., Abraham, W.M., Williams,
C.M., Clark, J.D., Liu, W.L., Clarke, N.P., Yeadon, M., 2012. Preclinical evaluation of
an inhibitor of cytosolic phospholipase A2alpha for the treatment of asthma.
J. Pharmacol. Exp. Ther. 340, 656–665.
Hulsmann, A.R., de Jongste, J.C., 1993. Studies of human airways in vitro: a review of
the methodology. J. Pharmacol. Toxicol. Methods 30, 117–132.
Iglarz, M., Binkert, C., Morrison, K., Fischli, W., Gatﬁeld, J., Treiber, A., Weller, T.,
Bolli, M.H., Boss, C., Buchmann, S., Capeleto, B., Hess, P., Qiu, C., Clozel, M., 2008.
Pharmacology of macitentan, an orally active tissue-targeting dual endothelin
receptor antagonist. J. Pharmacol. Exp. Ther. 327, 736–745.
Lee, S.I., 2010. Drug interaction: focusing on response surface models. Korean J.
Anesthesiol. 58, 421–434.
Matera, M.G., Calzetta, L., Parascandolo, V., Curradi, G., Rogliani, P., Cazzola, M.,
2009. Relaxant effect of brain natriuretic peptide in nonsensitized and passively
sensitized isolated human bronchi. Pulm. Pharmacol. Ther. 22, 478–482.
Matera, M.G., Calzetta, L., Passeri, D., Facciolo, F., Rendina, E.A., Page, C., Cazzola, M.,
Orlandi, A., 2011a. Epithelium integrity is crucial for the relaxant activity of
brain natriuretic peptide in human isolated bronchi. Br. J. Pharmacol. 163,
1740–1754.
Matera, M.G., Calzetta, L., Peli, A., Scagliarini, A., Matera, C., Cazzola, M., 2005.
Immune sensitization of equine bronchus: glutathione, IL-1beta expression and
tissue responsiveness. Respir. Res. 6, 104.
Matera, M.G., Calzetta, L., Rogliani, P., Bardaro, F., Page, C.P., Cazzola, M., 2011b.
Evaluation of the effects of the R- and S-enantiomers of salbutamol on equine
isolated bronchi. Pulm. Pharmacol. Ther. 24, 221–226.
Matera, M.G., Calzetta, L., Sanduzzi, A., Page, C.P., Cazzola, M., 2008. Effects of
neuraminidase on equine isolated bronchi. Pulm. Pharmacol. Ther. 21, 624–629.
Meletiadis, J., Mouton, J.W., Meis, J.F., Verweij, P.E., 2003. In vitro drug interaction
modeling of combinations of azoles with terbinaﬁne against clinical Scedos-
porium proliﬁcans isolates. Antimicrob. Agents Chemother. 47, 106–117.
Meurs, H., Dekkers, B.G., Maarsingh, H., Halayko, A.J., Zaagsma, J., Gosens, R., 2013.
Muscarinic receptors on airway mesenchymal cells: novel ﬁndings for an
ancient target. Pulm. Pharmacol. Ther. 26, 145–155.
Motulsky, H., Christopoulos, A., 2004. Fitting Models to Biological Data Using Linear
and Nonlinear Regression: A Practical Guide to Curve Fitting. Oxford University
Press, Oxford.
Rodrigo, G.J., Plaza, V., Castro-Rodriguez, J.A., 2012. Comparison of three combined
pharmacological approaches with tiotropium monotherapy in stable moderate
to severe COPD: a systematic review. Pulm. Pharmacol. Ther. 25, 40–47.
Rogliani, P., Calzetta, L., Rendina, E.A., Massullo, D., Dauri, M., Rinaldi, B., Capuano,
A., Matera, M.G., 2013. The inﬂuence of propofol, remifentanil and lidocaine on
the tone of human bronchial smooth muscle. Pulm. Pharmacol. Ther. 26,
325–331.
Rossoni, G., Manfredi, B., Razzetti, R., Civelli, M., Berti, F., 2007. Positive interaction
of the novel beta2-agonist carmoterol and tiotropium bromide in the control of
airway changes induced by different challenges in guinea-pigs. Pulm. Pharma-
col. Ther. 20, 250–257.
Singh, D., Jones, P., Bateman, E., Korn, S., Serra, C., Molins, E., Caracta, C., Garcia Gil,
E., Leselbaum, A., 2014. Evaluation of the efﬁcacy and safety of two doses of
aclidinium and formoterol in ﬁxed-dose combination in patients with COPD:
the ACLIFORM study. Chest 145, 375A.
Sturton, G., Persson, C., Barnes, P.J., 2008. Small airways: an important but neglected
target in the treatment of obstructive airway diseases. Trends Pharmacol. Sci.
29, 340–345.
Tallarida, R.J., 2001. Drug synergism: its detection and applications. J. Pharmacol.
Exp. Ther. 298, 865–872.
Tashkin, D.P., Ferguson, G.T., 2013. Combination bronchodilator therapy in the
management of chronic obstructive pulmonary disease. Respir. Res. 14, 49.
van Lunteren, E., Moyer, M., 2001. Auxotonic contractile responses of rat tracheal
and bronchial airway smooth muscle. Pulm. Pharmacol. Ther. 14, 443–453.
Wohlsen, A., Uhlig, S., Martin, C., 2001. Immediate allergic response in small
airways. Am. J. Respir. Crit. Care Med. 163, 1462–1469.
M. Cazzola et al. / European Journal of Pharmacology 745 (2014) 135–143 143
